Desarrollo de un framework en C# para control de arduino uno

El internet de las cosas se define de forma general, como la interacción de objetos de la vida cotidiana con los seres humanos y es uno de los temas de investigación más importantes de nuestros tiempos, sin embargo, en México no se tiene el avance que se espera de un país con su nivel de desarrollo. Las razones de esto son la baja divulgación de este tema en las universidades y en general en las escuelas; el nivel de complejidad, ya que se requiere conocer temas de programación, electrónica, sistemas digitales y comunicaciones y el tiempo de desarrollo, debido a que es necesario escribir código en dos lenguajes diferentes, el de la placa de desarrollo y otro de alto nivel. Este trabajo se centra en mostrar a los profesionales de la computación y a los interesados en el uso de IoT la forma de desarrollar aplicaciones con el uso de la placa Arduino y C#, además, como resultado del trabajo de investigación, se genera un marco de trabajo para la elaboración rápida de aplicaciones de este tipo

Brainwaves feature classification by applying K-Means clustering using single-sensor EEG

The use of brainwave signal is a step in the introduction of the individual identity using biometric technology based on characteristics of the body. Brainwave signal has unique characteristics and different on each individual because the brainwave cannot be read or copied by people so it is not possible to have a similarity of one person with another person. To be able to process the identification of individual characteristics, which obtained from the signal brainwave, required a pattern of brain activity that is prominent and constant. Cognitive activity testing using a single-sensor EEG (Electroencephalogram) divided into two categories, called the activity of cognitive involving the ability of the right brain (creativity, imagination, holistic thinking, intuition, arts, rhythms, nonverbal, feelings, visualization, tune of songs, daydreaming) and the left brain (logic, analysis, sequences, linear, mathematics, language, facts, think in words, word of songs, computation) give a different cluster based on two times the test on mathematical activities (no cluster slices of experiment 1 and experiment 2). The result showed that cognitive activity based on math activity can provide a signal characteristic that can be used as the basis for a brain-computer interface applications development by utilizing EEG single-sensor

Energy Efficiency Metrics of University Data Centers

The data centers are fundamental pieces in the network and computing infrastructure, and evidently today more than ever they are relevant. Since they support the processing, analysis, assurance of the data generated in the network and by the applications in the cloud, which every day increases its volume thanks to technologies such as Internet of Things, Virtualization, and cloud computing, among others. Precisely the management of this large volume of information makes the data centers consume a lot of energy, generating great concern to owners and administrators. Green Data Centers offer a solution to this problem, reducing the impact produced by the data centers in the environment, through the monitoring and control of these. The metrics are the tools that allow us to measure in our case the energy efficiency of the data center and evaluate if it is friendly to the environment. These metrics will be applied to the data centers of the ITSA University Institution, Barranquilla and Soledad campus, and the analysis of these will be carried out. In previous research, the most common metric (PUE) was analyzed to measure the efficiency of the data centers, to verify if the University's data center is friendly to the environment. It is planned to extend this study by carrying out an analysis of several metrics to conclude which is the most efficient and which allows defining the guidelines to update or convert the data center in a friendly environment.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis

BACKGROUND: To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL). METHODS: Patients received cemiplimab 3 mg/kg every 2 weeks (group 1, metastatic CSCC [mCSCC], n=59; group 2, locally advanced CSCC, n=78) or cemiplimab 350 mg every 3 weeks (group 3, mCSCC, n=56). Primary endpoint was objective response rate (ORR) per independent central review (ICR). QoL was repeatedly measured at day 1 of each treatment cycle (groups 1 and 2: 8 weeks; group 3: 9 weeks). RESULTS: Median duration of follow-up was 15.7 months. Overall, ORR per ICR was 46.1% (95% CI: 38.9% to 53.4%). Complete response (CR) rates were 20.3%, 12.8%, and 16.1% for groups 1, 2, and 3, respectively. Median time to CR was 11.2 months. Among patients with partial response or CR, the estimated proportion of patients with ongoing response at 12 months from the first objective response was 87.8% (95% CI: 78.5% to 93.3%), with median DOR not reached. Kaplan-Meier estimated probability of overall survival (OS) was 73.3% (95% CI: 66.1% to 79.2%) at 24 months, with median OS not reached. Global Health Status (GHS)/QoL improvements were observed as early as cycle 2 and were significantly improved and durable until last assessment. Kaplan-Meier estimate of median time to first clinically meaningful improvement for pain was 2.1 (95% CI: 2.0 to 3.7) months and was significantly improved in responders versus non-responders (p\u3c0.0001). CONCLUSIONS: This is the largest (n=193) clinical dataset for a programmed cell death-1 inhibitor against advanced CSCC, confirming the sustained substantial clinical activity of cemiplimab in these patients, including new findings of improved CR rates over time, increasing DOR, and durable pain control and GHS/QoL improvement. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT02760498), https://clinicaltrialsgov/ct2/show/NCT02760498

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing

BACKGROUND: Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we report the primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) and provide a longer-term update after the primary analysis of weight-based cemiplimab 3 mg/kg intravenously every 2 weeks (Q2W) (Group 1) among metastatic CSCC (mCSCC) patients in the pivotal study (NCT02760498). METHODS: The primary objective for each group was objective response rate (ORR) per independent central review (ICR). Secondary endpoints included ORR by investigator review (INV), duration of response (DOR) per ICR and INV, and safety and tolerability. RESULTS: For Group 3 (n=56) and Group 1 (n=59), median follow-up was 8.1 (range, 0.6 to 14.1) and 16.5 (range, 1.1 to 26.6) months, respectively. ORR per ICR was 41.1% (95% CI, 28.1% to 55.0%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 45.2% (95% CI, 35.9% to 54.8%) in both groups combined. Per ICR, Kaplan-Meier estimate for DOR at 8 months was 95.0% (95% CI, 69.5% to 99. 3%) in responding patients in Group 3, and at 12 months was 88.9% (95% CI, 69.3% to 96.3%) in responding patients in Group 1. Per INV, ORR was 51.8% (95% CI, 38.0% to 65.3%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 50.4% (95% CI, 41.0% to 59.9%) in both groups combined. Overall, the most common adverse events regardless of attribution were fatigue (27.0%) and diarrhea (23.5%). CONCLUSION: In patients with mCSCC, cemiplimab 350 mg intravenously Q3W produced substantial antitumor activity with durable response and an acceptable safety profile. Follow-up data of cemiplimab 3 mg/kg intravenously Q2W demonstrate ongoing durability of responses. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov, NCT02760498. Registered May 3, 2016, https://clinicaltrials.gov/ct2/show/NCT02760498

DESCENTRALIZACIÓN Y RECUPERACIÓN SOCIAL DEL TERRITORIO

Twenty years after the Colombian PoliticalConstitution was signed, the current researchaims at analyzing the state of thatdecentralizing alternative, taking into accounttwo essential elements – the democratization inthe exercise of the local power, and the responsibilities and the fiscal autonomy of the territorial entities, to the light of a governmental strategy of the Uribe Government – the socalled Social Recovery of the Territory -, within a concrete plan of a national government – the Frame Plan for the Integral Recovery of “Montes de María–” and several Municipal Development Plans, such as those from El Carmen de Bolívar, San Onofre, San Jacinto and Ovejas

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2-10%), the 1 year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8 months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

BACKGROUND: Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. METHODS: Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. RESULTS: For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients \u3c60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). CONCLUSIONS: Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. TRIAL REGISTRATION NUMBER: NCT01546571

Videojuegos y alteridad cultural: difusión de la cultura kumiai a través del diseño de advergame

171 páginas. Doctorado en Diseño.El presente documento propone una reflexión en torno al rol que el diseñador de videojuegos puede desempeñar en la preservación de la cultura nativa de Baja California, entendiéndose a sí mismo como un agente de difusión cultural, y al videojuego como un potencial objeto comunicativo. La reflexión parte de los supuestos acerca de la naturaleza lúdica del hombre abordados desde las teorías Aristóteles y Santo Tomás de Aquino, hasta Huizinga y Caillois. Posteriormente se visualiza la evolución de nuestros entornos de juego hacia los videojuegos y el potencial formativo de los mismos como objetos culturales figurativos. En consecuencia, se propone el desarrollo de un proyecto particular de diseño de videojuego en modalidad advergame, que funcione para intervenir en la problemática específica de etnodesarrollo de la cultura Kumiai de Baja California. Con base en la investigación etnográfica realizada, se explica la metodología utilizada para determinar el arte conceptual, diseño de personajes y construcción de la estructura narrativa para el prototipo del videojuego La senda de Jatñil, considerando las respectivas fundamentaciones teóricas y metodológicas

Juegos matemáticos como estrategia para la enseñanza y motivación en secundaria

Una forma de motivar a los estudiantes de secundaria y hacerles ver la matemática de forma atractiva es por medio de juegos con contenido matemático. En este taller se desarrollarán juegos matemáticos con el fin de mostrar al profesor de secundaria su posible uso para desarrollar algunos temas concretos, además de servir como una forma de motivar a los estudiantes y detectar jóvenes con aptitudes para participar en las Olimpiadas Costarricenses de Matemática. Se espera, asimismo, desarrollar la inquietud en los participantes para que investiguen más sobre el tema